Amylyx Pharmaceuticals, Inc.
AMLX
Classificação em ações
#4584
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Preço da ação
$26.52
Valor de mercado
$3.33B
Variação (1 dia)
0.68%
Variação (1 ano)
77.38%
País
US
Negociar Amylyx Pharmaceuticals, Inc. (AMLX)
Categoria
Healthcare
EPS de Amylyx Pharmaceuticals, Inc. (AMLX)
EPS em June 2026 TTM: $-1.41
De acordo com os últimos relatórios financeiros e o preço das ações da Amylyx Pharmaceuticals, Inc., o EPS atual da empresa (TTM) é $-1.41. No final de 2023, a empresa teve um EPS de $0.73, um aumento em relação a ao EPS de 2022, que foi de $-2.98.
Histórico de EPS da Amylyx Pharmaceuticals, Inc. de 2019 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
